http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-112013030552-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2f4552bec9a852244269a330fda1c754 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cdb48577f62fd97bad781d9ca6a562fe http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_53b51023cba19b07f3c7d1ea52a1b13d |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-522 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-015 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P33-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-015 |
| filingDate | 2012-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1efb6a0be392cb77f450517c5d647d0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d195fe5b9b9662c4641f0fbafd280aa9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e0b6931aea0e9421b513d6e5efd96cc1 |
| publicationDate | 2022-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-112013030552-B1 |
| titleOfInvention | Immunogenic composition, in vitro method for producing said immunogenic composition and use thereof to prevent or inhibit a malarial infection or to treat an existing malarial infection |
| abstract | method for producing an immunogenic composition, immunogenic composition and use of said immunogenic composition. The present invention relates to an immunogenic composition for use as a vaccine against blood phase malaria, a method of producing the immunogenic composition and a method of treating malaria. the immunogenic composition includes isolated or purified merozoites, or merozoite-infected red blood cells treated with centanamycin or tafuramycin a. the immunogenic composition does not include an adjuvant. a single dose of the immunogenic composition is sufficient to protect an animal against subsequent malaria infection by the same plasmodium isolate, strain or species used in the immunogenic composition, or by one or more heterologous plasmodium isolates, strains or species. |
| priorityDate | 2011-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 76.